

anti-metabolic anti-cancer drugs are known to be fairly toxic and to provoke additional discomfort, including megaloblastose, and lesions to the liver or the digestive tract such as stomatitis and buccal and gastro-intestinal ulcers.--

Please replace the paragraph beginning at page 3, line 3 with the following rewritten paragraph:

--The disadvantages and drawbacks may considerably limit the use of available anti-cancer drugs. Indeed, often a curative effective dose of the drug cannot be given to a patient due to the too high toxicity of the drug to normal cells or to the too high degree of discomfort caused to the patient by the drug.--

Please replace the paragraph beginning at page 13, line 1 with the following rewritten paragraph:

--In all the experiments a chemotherapy potentiating effect has been observed for dietary FOS or inulin. Obviously this therapeutic effect was somewhat different for the various drugs. Only for 5-fluorouracil treatment a synergistic therapeutic effect has been observed. For treatment with oncovin, endoxan and adriamycin, the therapeutic effects had only additive character. There is no significant difference observed between treatment with inulin or FOS.--

**IN THE CLAIMS:**

Kindly cancel claim 34, without prejudice.

Please amend claims 21-24, 26-29, 32, 33 and 35, to read as follows:

21. (Amended) Pharmaceutical composition characterized by comprising a combination of an effective dose of inulin and of an anti-metabolic anti-cancer drug, said combination providing a synergistic anti-cancer effect.